Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Anti-tumor immunity

cDC1 craves glutamine for its glory

Nature Immunology volume 24, pages 1405–1406 (2023)Cite this article

Subjects

A recent study shows how intratumoral glutamine supplementation can improve the function of tumor-infiltrating dendritic cells and enhance the CD8+ T cell anti-tumor response.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Glutamine and anti-tumor responses.

References

  1. Cheng, W.-C. et al. Nat. Immunol. 20, 206–217 (2019).

    Article  CAS  PubMed  Google Scholar 

  2. Böttcher, J. P. & Reis e Sousa, C. Trends Cancer 4, 784–792 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lin, J. H. et al. J. Exp. Med. 217, e20190673 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bayerl, F. et al. Immunity 56, 1341–1358 (2023).

    Article  CAS  PubMed  Google Scholar 

  5. Kao, K.-C., Vilbois, S., Tsai, C.-H. & Ho, P.-C. Nat. Cell. Biol. 24, 1574–1583 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Jin, J., Byun, J.-K., Choi, Y.-K. & Park, K.-G. Exp. Mol. Med. 55, 706–715 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Leone, R. D. et al. Science 366, 1013–1021 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Edwards, D. N. et al. J. Clin. Invest. 131, (2021).

  9. Best, S. A. et al. Cell Metab. 34, 874–887 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Guo, C. et al. Nature 620, 200–208 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Stefania Vilbois, Jaeoh Park.

Authors and Affiliations

  1. Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland

    Stefania Vilbois, Jaeoh Park & Ping-Chih Ho

  2. Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland

    Stefania Vilbois, Jaeoh Park & Ping-Chih Ho

Authors
  1. Stefania Vilbois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaeoh Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping-Chih Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping-Chih Ho.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vilbois, S., Park, J. & Ho, PC. cDC1 craves glutamine for its glory. Nat Immunol 24, 1405–1406 (2023). https://doi.org/10.1038/s41590-023-01598-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01598-8

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing